» Articles » PMID: 31676847

Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma After Orthotopic Liver Transplantation

Overview
Journal Sci Rep
Specialty Science
Date 2019 Nov 3
PMID 31676847
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinomas(HCC) consisted of heterogeneous subtypes with different recurrence probabilities after liver transplantation(LT). Our study aimed to develop an improved model for predicting the recurrence of solitary HCC after LT. In this retrospective study, 151 solitary HCC patients who received orthotopic LT over a period of 10 consecutive years were included. All recipients received graft from deceased donors. The first eligible 50 patients were used as validation cohort and others were utilized to construct the model. A two-tailed P < 0.05 was considered to indicate statistical significance for all analysis. Based on the maximisation of the Youden's index, the optimal cutoff values for alpha-fetoprotein(AFP) and tumor diameter were 261.6 ng/mL and 3.6 cm, respectively. Vascular involvement includes gross and microscopic vascular invasion. Variables potentially affecting recurrence-free survival(RFS) were examined using univariate and multivariate Cox regression analysis. Univariate and multivariate analysis revealed that AFP, tumor diameter, vascular invasion and cytokeratin-19/glypican-3 sub-typing were independent prognostic factors for RFS, thus comprised the risk scoring model. The AUC values of the model in the cohorts were significantly higher than that of the Milan, UCSF, Fudan and Hangzhou criteria. These findings suggest the model has high performance in predicting early recurrence of solitary HCC patients after LT.

Citing Articles

α-Fetoprotein, α-Fetoprotein-L3, and Des-γ-Carboxy Prothrombin Stratify Hepatocellular Carcinoma Treatment Response and Progression Risk.

Nunez K, Schneider M, Sandow T, Gimenez J, Hibino M, Fort D Gastro Hep Adv. 2024; 3(3):316-325.

PMID: 39131145 PMC: 11308544. DOI: 10.1016/j.gastha.2023.11.018.


Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies.

Shannon A, Ruff S, Schenk A, Washburn K, Pawlik T Medicina (Kaunas). 2023; 59(7).

PMID: 37512101 PMC: 10383519. DOI: 10.3390/medicina59071290.


A multiomic ferroptosis-associated prognostic signature incorporating epigenetic and transcriptional biomarkers for hepatocellular carcinoma.

Chen J, Zhu X, Chen D, Jin L, Xu W, Yu W Transl Cancer Res. 2022; 11(7):1889-1897.

PMID: 35966333 PMC: 9372242. DOI: 10.21037/tcr-21-2882.


Orthotopic liver transplantation improves postoperative quality of life, survival rate and reduces recurrence rate in patients with liver cancer.

Zhang X, Lv L, Wu Z, Li D, Zhang K, Peng Y Am J Transl Res. 2022; 14(2):990-1000.

PMID: 35273701 PMC: 8902539.


Re-Recognizing the Cellular Origin of the Primary Epithelial Tumors of the Liver.

Feng J, Zhu R, Yin Y, Wang S, Zhou L, Lv F J Hepatocell Carcinoma. 2021; 8:1537-1563.

PMID: 34917552 PMC: 8668194. DOI: 10.2147/JHC.S334935.


References
1.
Teng F, Han Q, Ding G, Ni Z, Fu H, Guo W . Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. Sci Rep. 2015; 5:11733. PMC: 4476095. DOI: 10.1038/srep11733. View

2.
Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G . CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PLoS One. 2016; 11(3):e0151501. PMC: 4792431. DOI: 10.1371/journal.pone.0151501. View

3.
Feo F, Pascale R . Multifocal hepatocellular carcinoma: intrahepatic metastasis or multicentric carcinogenesis?. Ann Transl Med. 2015; 3(1):4. PMC: 4293477. DOI: 10.3978/j.issn.2305-5839.2014.12.08. View

4.
Grozdanov P, Yovchev M, Dabeva M . The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006; 86(12):1272-84. DOI: 10.1038/labinvest.3700479. View

5.
Feng J, Chen J, Zhu R, Yu L, Zhang Y, Feng D . Prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after radical resection. Oncotarget. 2017; 8(38):63299-63310. PMC: 5609922. DOI: 10.18632/oncotarget.18799. View